Advertisement

Index by author

January 01, 1995; Volume 23,Issue 1

A

  1. Anders, M W

    1. Metabolism of [14C]- and [35S]S-(1,2-dichlorovinyl)-L-cysteine in the male Fischer 344 rat.
      M B Finkelstein, N J Patel and M W Anders
      Drug Metabolism and Disposition January 1995, 23 (1) 124-128;
    2. Biosynthesis of S-(2-chloro-1,1,2-trifluoroethyl)glutathione in rat and human hepatocytes and in Hep G2 cells.
      E Tanaka and M W Anders
      Drug Metabolism and Disposition January 1995, 23 (1) 48-54;

  2. Andersson, P

    1. Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver.
      G Jönsson, A Aström and P Andersson
      Drug Metabolism and Disposition January 1995, 23 (1) 137-142;

  3. Aström, A

    1. Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver.
      G Jönsson, A Aström and P Andersson
      Drug Metabolism and Disposition January 1995, 23 (1) 137-142;

B

  1. Baker, M T

    1. Isoflurane-chlorodifluoroethene interaction in human liver microsomes. Role of cytochrome P4502B6 in potentiation of haloethene metabolism.
      M T Baker, M J Olson, Y Wang, W C Ronnenberg, J T Johnson and A N Brady
      Drug Metabolism and Disposition January 1995, 23 (1) 60-64;

  2. Benfenati, E

    1. Fate of 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (ET18-OME) in malignant cells, normal cells, and isolated and perfused rat liver.
      A Magistrelli, P Villa, E Benfenati, E J Modest, M Salmona and M T Tacconi
      Drug Metabolism and Disposition January 1995, 23 (1) 113-118;

  3. Blanz, J

    1. Biotransformation of CI-937 in primary cultures of rat hepatocytes. Formation of glutathione conjugates.
      U Renner, J Blanz, S Freund, D Waidelich, G Ehninger and K P Zeller
      Drug Metabolism and Disposition January 1995, 23 (1) 94-101;

  4. Boado, R J

    1. Pharmacokinetics and organ clearance of a 3'-biotinylated, internally [32P]-labeled phosphodiester oligodeoxynucleotide coupled to a neutral avidin/monoclonal antibody conjugate.
      Y S Kang, R J Boado and W M Pardridge
      Drug Metabolism and Disposition January 1995, 23 (1) 55-59;

  5. Brady, A N

    1. Isoflurane-chlorodifluoroethene interaction in human liver microsomes. Role of cytochrome P4502B6 in potentiation of haloethene metabolism.
      M T Baker, M J Olson, Y Wang, W C Ronnenberg, J T Johnson and A N Brady
      Drug Metabolism and Disposition January 1995, 23 (1) 60-64;

  6. Brewer, T G

    1. Side-chain hydroxylation in the metabolism of 8-aminoquinoline antiparasitic agents.
      O R Idowu, J O Peggins and T G Brewer
      Drug Metabolism and Disposition January 1995, 23 (1) 18-27;
    2. Metabolism of a candidate 8-aminoquinoline antimalarial agent, WR 238605, by rat liver microsomes.
      O R Idowu, J O Peggins, T G Brewer and C Kelley
      Drug Metabolism and Disposition January 1995, 23 (1) 1-17;

C

  1. Chauret, N

    1. In vitro and in vivo biotransformations of the naphthalenic lignan lactone 5-lipoxygenase inhibitor, L-702,539.
      N Chauret, C Li, Y Ducharme, L A Trimble, J A Yergey, C Ramachandran and D A Nicoll-Griffith
      Drug Metabolism and Disposition January 1995, 23 (1) 65-71;

  2. Chikai, T

    1. Ocular absorption, distribution, and systemic absorption of a novel antiglaucoma medication, prostaglandin derivative, in male white rabbits.
      K Higaki, K Kamata, M Takeuchi, K Inazawa, T Chikai, T Hamaguchi, T Yukawa, K Kadono, S Kawahara and M Nakano
      Drug Metabolism and Disposition January 1995, 23 (1) 35-43;

  3. Collins, M A

    1. Identification and quantification of fluorine-containing metabolites of 1-chloro-2,2,2-trifluoroethane (HCFC133A) in the rat by 19F-NMR spectroscopy.
      M K Ellis, J L Naylor, T Green and M A Collins
      Drug Metabolism and Disposition January 1995, 23 (1) 102-106;

  4. Creech Kraft, J

    1. Xenopus laevis: a model system for the study of embryonic retinoid metabolism. II. Embryonic metabolism of all-trans-3,4-didehydroretinol to all-trans-3,4-didehydroretinoic acid.
      J Creech Kraft, D Kimelman and M R Juchau
      Drug Metabolism and Disposition January 1995, 23 (1) 83-89;

D

  1. Dickinson, R G

    1. Characterization and formation of the glutathione conjugate of clofibric acid.
      L J Shore, C Fenselau, A R King and R G Dickinson
      Drug Metabolism and Disposition January 1995, 23 (1) 119-123;

  2. Ducharme, Y

    1. In vitro and in vivo biotransformations of the naphthalenic lignan lactone 5-lipoxygenase inhibitor, L-702,539.
      N Chauret, C Li, Y Ducharme, L A Trimble, J A Yergey, C Ramachandran and D A Nicoll-Griffith
      Drug Metabolism and Disposition January 1995, 23 (1) 65-71;

E

  1. Ehninger, G

    1. Biotransformation of CI-937 in primary cultures of rat hepatocytes. Formation of glutathione conjugates.
      U Renner, J Blanz, S Freund, D Waidelich, G Ehninger and K P Zeller
      Drug Metabolism and Disposition January 1995, 23 (1) 94-101;

  2. Ellis, M K

    1. Identification and quantification of fluorine-containing metabolites of 1-chloro-2,2,2-trifluoroethane (HCFC133A) in the rat by 19F-NMR spectroscopy.
      M K Ellis, J L Naylor, T Green and M A Collins
      Drug Metabolism and Disposition January 1995, 23 (1) 102-106;

F

  1. Fenselau, C

    1. Characterization and formation of the glutathione conjugate of clofibric acid.
      L J Shore, C Fenselau, A R King and R G Dickinson
      Drug Metabolism and Disposition January 1995, 23 (1) 119-123;

  2. Finkelstein, M B

    1. Metabolism of [14C]- and [35S]S-(1,2-dichlorovinyl)-L-cysteine in the male Fischer 344 rat.
      M B Finkelstein, N J Patel and M W Anders
      Drug Metabolism and Disposition January 1995, 23 (1) 124-128;

  3. Freund, S

    1. Biotransformation of CI-937 in primary cultures of rat hepatocytes. Formation of glutathione conjugates.
      U Renner, J Blanz, S Freund, D Waidelich, G Ehninger and K P Zeller
      Drug Metabolism and Disposition January 1995, 23 (1) 94-101;

  4. Fujii, Y

    1. Further metabolism of FK506 (tacrolimus). Identification and biological activities of the metabolites oxidized at multiple sites of FK506.
      K Iwasaki, T Shiraga, H Matsuda, K Nagase, Y Tokuma, T Hata, Y Fujii, S Sakuma, T Fujitsu and A Fujikawa
      Drug Metabolism and Disposition January 1995, 23 (1) 28-34;

  5. Fujikawa, A

    1. Further metabolism of FK506 (tacrolimus). Identification and biological activities of the metabolites oxidized at multiple sites of FK506.
      K Iwasaki, T Shiraga, H Matsuda, K Nagase, Y Tokuma, T Hata, Y Fujii, S Sakuma, T Fujitsu and A Fujikawa
      Drug Metabolism and Disposition January 1995, 23 (1) 28-34;

  6. Fujitsu, T

    1. Further metabolism of FK506 (tacrolimus). Identification and biological activities of the metabolites oxidized at multiple sites of FK506.
      K Iwasaki, T Shiraga, H Matsuda, K Nagase, Y Tokuma, T Hata, Y Fujii, S Sakuma, T Fujitsu and A Fujikawa
      Drug Metabolism and Disposition January 1995, 23 (1) 28-34;

G

  1. Gerstenberg, B

    1. Nicotine and cotinine accumulation in pigmented and unpigmented rat hair.
      B Gerstenberg, G Schepers, P Voncken and H Völkel
      Drug Metabolism and Disposition January 1995, 23 (1) 143-148;

  2. Green, T

    1. Identification and quantification of fluorine-containing metabolites of 1-chloro-2,2,2-trifluoroethane (HCFC133A) in the rat by 19F-NMR spectroscopy.
      M K Ellis, J L Naylor, T Green and M A Collins
      Drug Metabolism and Disposition January 1995, 23 (1) 102-106;

H

  1. Hamaguchi, T

    1. Ocular absorption, distribution, and systemic absorption of a novel antiglaucoma medication, prostaglandin derivative, in male white rabbits.
      K Higaki, K Kamata, M Takeuchi, K Inazawa, T Chikai, T Hamaguchi, T Yukawa, K Kadono, S Kawahara and M Nakano
      Drug Metabolism and Disposition January 1995, 23 (1) 35-43;

  2. Harvison, P J

    1. Metabolism of the nephrotoxicant N-(3,5-dichlorophenyl)succinimide by isolated rat hepatocytes.
      A K Nyarko and P J Harvison
      Drug Metabolism and Disposition January 1995, 23 (1) 107-112;

  3. Hata, T

    1. Further metabolism of FK506 (tacrolimus). Identification and biological activities of the metabolites oxidized at multiple sites of FK506.
      K Iwasaki, T Shiraga, H Matsuda, K Nagase, Y Tokuma, T Hata, Y Fujii, S Sakuma, T Fujitsu and A Fujikawa
      Drug Metabolism and Disposition January 1995, 23 (1) 28-34;

  4. Higaki, K

    1. Ocular absorption, distribution, and systemic absorption of a novel antiglaucoma medication, prostaglandin derivative, in male white rabbits.
      K Higaki, K Kamata, M Takeuchi, K Inazawa, T Chikai, T Hamaguchi, T Yukawa, K Kadono, S Kawahara and M Nakano
      Drug Metabolism and Disposition January 1995, 23 (1) 35-43;

  5. Holland, M L

    1. Pharmacokinetics and bioavailability of topiramate in the beagle dog.
      A J Streeter, P L Stahle, M L Holland, J F Pritchard and A R Takacs
      Drug Metabolism and Disposition January 1995, 23 (1) 90-93;

I

  1. Idowu, O R

    1. Side-chain hydroxylation in the metabolism of 8-aminoquinoline antiparasitic agents.
      O R Idowu, J O Peggins and T G Brewer
      Drug Metabolism and Disposition January 1995, 23 (1) 18-27;
    2. Metabolism of a candidate 8-aminoquinoline antimalarial agent, WR 238605, by rat liver microsomes.
      O R Idowu, J O Peggins, T G Brewer and C Kelley
      Drug Metabolism and Disposition January 1995, 23 (1) 1-17;

  2. Inazawa, K

    1. Ocular absorption, distribution, and systemic absorption of a novel antiglaucoma medication, prostaglandin derivative, in male white rabbits.
      K Higaki, K Kamata, M Takeuchi, K Inazawa, T Chikai, T Hamaguchi, T Yukawa, K Kadono, S Kawahara and M Nakano
      Drug Metabolism and Disposition January 1995, 23 (1) 35-43;

  3. Iwasaki, K

    1. Further metabolism of FK506 (tacrolimus). Identification and biological activities of the metabolites oxidized at multiple sites of FK506.
      K Iwasaki, T Shiraga, H Matsuda, K Nagase, Y Tokuma, T Hata, Y Fujii, S Sakuma, T Fujitsu and A Fujikawa
      Drug Metabolism and Disposition January 1995, 23 (1) 28-34;

J

  1. Johnson, J T

    1. Isoflurane-chlorodifluoroethene interaction in human liver microsomes. Role of cytochrome P4502B6 in potentiation of haloethene metabolism.
      M T Baker, M J Olson, Y Wang, W C Ronnenberg, J T Johnson and A N Brady
      Drug Metabolism and Disposition January 1995, 23 (1) 60-64;

  2. Jones, A D

    1. Metabolism of [14C]naphthalene in the B6C3F1 murine isolated perfused liver.
      L S Tsuruda, M W Lamé and A D Jones
      Drug Metabolism and Disposition January 1995, 23 (1) 129-136;

  3. Jönsson, G

    1. Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver.
      G Jönsson, A Aström and P Andersson
      Drug Metabolism and Disposition January 1995, 23 (1) 137-142;

  4. Juchau, M R

    1. Xenopus laevis: a model system for the study of embryonic retinoid metabolism. I. Embryonic metabolism of 9-cis- and all-trans-retinals and retinols to their corresponding acid forms.
      J C Kraft, D Kimelman and M R Juchau
      Drug Metabolism and Disposition January 1995, 23 (1) 72-82;
    2. Xenopus laevis: a model system for the study of embryonic retinoid metabolism. II. Embryonic metabolism of all-trans-3,4-didehydroretinol to all-trans-3,4-didehydroretinoic acid.
      J Creech Kraft, D Kimelman and M R Juchau
      Drug Metabolism and Disposition January 1995, 23 (1) 83-89;

K

  1. Kadono, K

    1. Ocular absorption, distribution, and systemic absorption of a novel antiglaucoma medication, prostaglandin derivative, in male white rabbits.
      K Higaki, K Kamata, M Takeuchi, K Inazawa, T Chikai, T Hamaguchi, T Yukawa, K Kadono, S Kawahara and M Nakano
      Drug Metabolism and Disposition January 1995, 23 (1) 35-43;

  2. Kamata, K

    1. Ocular absorption, distribution, and systemic absorption of a novel antiglaucoma medication, prostaglandin derivative, in male white rabbits.
      K Higaki, K Kamata, M Takeuchi, K Inazawa, T Chikai, T Hamaguchi, T Yukawa, K Kadono, S Kawahara and M Nakano
      Drug Metabolism and Disposition January 1995, 23 (1) 35-43;

  3. Kang, Y S

    1. Pharmacokinetics and organ clearance of a 3'-biotinylated, internally [32P]-labeled phosphodiester oligodeoxynucleotide coupled to a neutral avidin/monoclonal antibody conjugate.
      Y S Kang, R J Boado and W M Pardridge
      Drug Metabolism and Disposition January 1995, 23 (1) 55-59;

  4. Kawahara, S

    1. Ocular absorption, distribution, and systemic absorption of a novel antiglaucoma medication, prostaglandin derivative, in male white rabbits.
      K Higaki, K Kamata, M Takeuchi, K Inazawa, T Chikai, T Hamaguchi, T Yukawa, K Kadono, S Kawahara and M Nakano
      Drug Metabolism and Disposition January 1995, 23 (1) 35-43;

  5. Kelley, C

    1. Metabolism of a candidate 8-aminoquinoline antimalarial agent, WR 238605, by rat liver microsomes.
      O R Idowu, J O Peggins, T G Brewer and C Kelley
      Drug Metabolism and Disposition January 1995, 23 (1) 1-17;

  6. Kimelman, D

    1. Xenopus laevis: a model system for the study of embryonic retinoid metabolism. I. Embryonic metabolism of 9-cis- and all-trans-retinals and retinols to their corresponding acid forms.
      J C Kraft, D Kimelman and M R Juchau
      Drug Metabolism and Disposition January 1995, 23 (1) 72-82;
    2. Xenopus laevis: a model system for the study of embryonic retinoid metabolism. II. Embryonic metabolism of all-trans-3,4-didehydroretinol to all-trans-3,4-didehydroretinoic acid.
      J Creech Kraft, D Kimelman and M R Juchau
      Drug Metabolism and Disposition January 1995, 23 (1) 83-89;

  7. King, A R

    1. Characterization and formation of the glutathione conjugate of clofibric acid.
      L J Shore, C Fenselau, A R King and R G Dickinson
      Drug Metabolism and Disposition January 1995, 23 (1) 119-123;

  8. Kraft, J C

    1. Xenopus laevis: a model system for the study of embryonic retinoid metabolism. I. Embryonic metabolism of 9-cis- and all-trans-retinals and retinols to their corresponding acid forms.
      J C Kraft, D Kimelman and M R Juchau
      Drug Metabolism and Disposition January 1995, 23 (1) 72-82;

L

  1. Lamé, M W

    1. Metabolism of [14C]naphthalene in the B6C3F1 murine isolated perfused liver.
      L S Tsuruda, M W Lamé and A D Jones
      Drug Metabolism and Disposition January 1995, 23 (1) 129-136;

  2. Li, C

    1. In vitro and in vivo biotransformations of the naphthalenic lignan lactone 5-lipoxygenase inhibitor, L-702,539.
      N Chauret, C Li, Y Ducharme, L A Trimble, J A Yergey, C Ramachandran and D A Nicoll-Griffith
      Drug Metabolism and Disposition January 1995, 23 (1) 65-71;

  3. Lu, A Y

    1. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes.
      D J Newton, R W Wang and A Y Lu
      Drug Metabolism and Disposition January 1995, 23 (1) 154-158;

M

  1. Magistrelli, A

    1. Fate of 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (ET18-OME) in malignant cells, normal cells, and isolated and perfused rat liver.
      A Magistrelli, P Villa, E Benfenati, E J Modest, M Salmona and M T Tacconi
      Drug Metabolism and Disposition January 1995, 23 (1) 113-118;

  2. Matsuda, H

    1. Further metabolism of FK506 (tacrolimus). Identification and biological activities of the metabolites oxidized at multiple sites of FK506.
      K Iwasaki, T Shiraga, H Matsuda, K Nagase, Y Tokuma, T Hata, Y Fujii, S Sakuma, T Fujitsu and A Fujikawa
      Drug Metabolism and Disposition January 1995, 23 (1) 28-34;

  3. Modest, E J

    1. Fate of 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (ET18-OME) in malignant cells, normal cells, and isolated and perfused rat liver.
      A Magistrelli, P Villa, E Benfenati, E J Modest, M Salmona and M T Tacconi
      Drug Metabolism and Disposition January 1995, 23 (1) 113-118;

  4. Monshouwer, M

    1. Infection (Actinobacillus pleuropneumoniae)-mediated suppression of oxidative hepatic drug metabolism and cytochrome P4503A mRNA levels in pigs.
      M Monshouwer, R F Witkamp, S M Nijmeijer, L A Van Leengoed, J H Verheijden and A S Van Miert
      Drug Metabolism and Disposition January 1995, 23 (1) 44-47;

N

  1. Nagase, K

    1. Further metabolism of FK506 (tacrolimus). Identification and biological activities of the metabolites oxidized at multiple sites of FK506.
      K Iwasaki, T Shiraga, H Matsuda, K Nagase, Y Tokuma, T Hata, Y Fujii, S Sakuma, T Fujitsu and A Fujikawa
      Drug Metabolism and Disposition January 1995, 23 (1) 28-34;

  2. Nakano, M

    1. Ocular absorption, distribution, and systemic absorption of a novel antiglaucoma medication, prostaglandin derivative, in male white rabbits.
      K Higaki, K Kamata, M Takeuchi, K Inazawa, T Chikai, T Hamaguchi, T Yukawa, K Kadono, S Kawahara and M Nakano
      Drug Metabolism and Disposition January 1995, 23 (1) 35-43;

  3. Naylor, J L

    1. Identification and quantification of fluorine-containing metabolites of 1-chloro-2,2,2-trifluoroethane (HCFC133A) in the rat by 19F-NMR spectroscopy.
      M K Ellis, J L Naylor, T Green and M A Collins
      Drug Metabolism and Disposition January 1995, 23 (1) 102-106;

  4. Nellans, H N

    1. Stereoselective glucuronidation of zileuton isomers by human hepatic microsomes.
      D J Sweeny and H N Nellans
      Drug Metabolism and Disposition January 1995, 23 (1) 149-153;

  5. Newton, D J

    1. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes.
      D J Newton, R W Wang and A Y Lu
      Drug Metabolism and Disposition January 1995, 23 (1) 154-158;

  6. Nicoll-Griffith, D A

    1. In vitro and in vivo biotransformations of the naphthalenic lignan lactone 5-lipoxygenase inhibitor, L-702,539.
      N Chauret, C Li, Y Ducharme, L A Trimble, J A Yergey, C Ramachandran and D A Nicoll-Griffith
      Drug Metabolism and Disposition January 1995, 23 (1) 65-71;

  7. Nijmeijer, S M

    1. Infection (Actinobacillus pleuropneumoniae)-mediated suppression of oxidative hepatic drug metabolism and cytochrome P4503A mRNA levels in pigs.
      M Monshouwer, R F Witkamp, S M Nijmeijer, L A Van Leengoed, J H Verheijden and A S Van Miert
      Drug Metabolism and Disposition January 1995, 23 (1) 44-47;

  8. Nyarko, A K

    1. Metabolism of the nephrotoxicant N-(3,5-dichlorophenyl)succinimide by isolated rat hepatocytes.
      A K Nyarko and P J Harvison
      Drug Metabolism and Disposition January 1995, 23 (1) 107-112;

O

  1. Olson, M J

    1. Isoflurane-chlorodifluoroethene interaction in human liver microsomes. Role of cytochrome P4502B6 in potentiation of haloethene metabolism.
      M T Baker, M J Olson, Y Wang, W C Ronnenberg, J T Johnson and A N Brady
      Drug Metabolism and Disposition January 1995, 23 (1) 60-64;

P

  1. Pardridge, W M

    1. Pharmacokinetics and organ clearance of a 3'-biotinylated, internally [32P]-labeled phosphodiester oligodeoxynucleotide coupled to a neutral avidin/monoclonal antibody conjugate.
      Y S Kang, R J Boado and W M Pardridge
      Drug Metabolism and Disposition January 1995, 23 (1) 55-59;

  2. Patel, N J

    1. Metabolism of [14C]- and [35S]S-(1,2-dichlorovinyl)-L-cysteine in the male Fischer 344 rat.
      M B Finkelstein, N J Patel and M W Anders
      Drug Metabolism and Disposition January 1995, 23 (1) 124-128;

  3. Peggins, J O

    1. Side-chain hydroxylation in the metabolism of 8-aminoquinoline antiparasitic agents.
      O R Idowu, J O Peggins and T G Brewer
      Drug Metabolism and Disposition January 1995, 23 (1) 18-27;
    2. Metabolism of a candidate 8-aminoquinoline antimalarial agent, WR 238605, by rat liver microsomes.
      O R Idowu, J O Peggins, T G Brewer and C Kelley
      Drug Metabolism and Disposition January 1995, 23 (1) 1-17;

  4. Pritchard, J F

    1. Pharmacokinetics and bioavailability of topiramate in the beagle dog.
      A J Streeter, P L Stahle, M L Holland, J F Pritchard and A R Takacs
      Drug Metabolism and Disposition January 1995, 23 (1) 90-93;

R

  1. Ramachandran, C

    1. In vitro and in vivo biotransformations of the naphthalenic lignan lactone 5-lipoxygenase inhibitor, L-702,539.
      N Chauret, C Li, Y Ducharme, L A Trimble, J A Yergey, C Ramachandran and D A Nicoll-Griffith
      Drug Metabolism and Disposition January 1995, 23 (1) 65-71;

  2. Renner, U

    1. Biotransformation of CI-937 in primary cultures of rat hepatocytes. Formation of glutathione conjugates.
      U Renner, J Blanz, S Freund, D Waidelich, G Ehninger and K P Zeller
      Drug Metabolism and Disposition January 1995, 23 (1) 94-101;

  3. Ronnenberg, W C

    1. Isoflurane-chlorodifluoroethene interaction in human liver microsomes. Role of cytochrome P4502B6 in potentiation of haloethene metabolism.
      M T Baker, M J Olson, Y Wang, W C Ronnenberg, J T Johnson and A N Brady
      Drug Metabolism and Disposition January 1995, 23 (1) 60-64;

S

  1. Sakuma, S

    1. Further metabolism of FK506 (tacrolimus). Identification and biological activities of the metabolites oxidized at multiple sites of FK506.
      K Iwasaki, T Shiraga, H Matsuda, K Nagase, Y Tokuma, T Hata, Y Fujii, S Sakuma, T Fujitsu and A Fujikawa
      Drug Metabolism and Disposition January 1995, 23 (1) 28-34;

  2. Salmona, M

    1. Fate of 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (ET18-OME) in malignant cells, normal cells, and isolated and perfused rat liver.
      A Magistrelli, P Villa, E Benfenati, E J Modest, M Salmona and M T Tacconi
      Drug Metabolism and Disposition January 1995, 23 (1) 113-118;

  3. Schepers, G

    1. Nicotine and cotinine accumulation in pigmented and unpigmented rat hair.
      B Gerstenberg, G Schepers, P Voncken and H Völkel
      Drug Metabolism and Disposition January 1995, 23 (1) 143-148;

  4. Shiraga, T

    1. Further metabolism of FK506 (tacrolimus). Identification and biological activities of the metabolites oxidized at multiple sites of FK506.
      K Iwasaki, T Shiraga, H Matsuda, K Nagase, Y Tokuma, T Hata, Y Fujii, S Sakuma, T Fujitsu and A Fujikawa
      Drug Metabolism and Disposition January 1995, 23 (1) 28-34;

  5. Shore, L J

    1. Characterization and formation of the glutathione conjugate of clofibric acid.
      L J Shore, C Fenselau, A R King and R G Dickinson
      Drug Metabolism and Disposition January 1995, 23 (1) 119-123;

  6. Stahle, P L

    1. Pharmacokinetics and bioavailability of topiramate in the beagle dog.
      A J Streeter, P L Stahle, M L Holland, J F Pritchard and A R Takacs
      Drug Metabolism and Disposition January 1995, 23 (1) 90-93;

  7. Streeter, A J

    1. Pharmacokinetics and bioavailability of topiramate in the beagle dog.
      A J Streeter, P L Stahle, M L Holland, J F Pritchard and A R Takacs
      Drug Metabolism and Disposition January 1995, 23 (1) 90-93;

  8. Sweeny, D J

    1. Stereoselective glucuronidation of zileuton isomers by human hepatic microsomes.
      D J Sweeny and H N Nellans
      Drug Metabolism and Disposition January 1995, 23 (1) 149-153;

T

  1. Tacconi, M T

    1. Fate of 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (ET18-OME) in malignant cells, normal cells, and isolated and perfused rat liver.
      A Magistrelli, P Villa, E Benfenati, E J Modest, M Salmona and M T Tacconi
      Drug Metabolism and Disposition January 1995, 23 (1) 113-118;

  2. Takacs, A R

    1. Pharmacokinetics and bioavailability of topiramate in the beagle dog.
      A J Streeter, P L Stahle, M L Holland, J F Pritchard and A R Takacs
      Drug Metabolism and Disposition January 1995, 23 (1) 90-93;

  3. Takeuchi, M

    1. Ocular absorption, distribution, and systemic absorption of a novel antiglaucoma medication, prostaglandin derivative, in male white rabbits.
      K Higaki, K Kamata, M Takeuchi, K Inazawa, T Chikai, T Hamaguchi, T Yukawa, K Kadono, S Kawahara and M Nakano
      Drug Metabolism and Disposition January 1995, 23 (1) 35-43;

  4. Tanaka, E

    1. Biosynthesis of S-(2-chloro-1,1,2-trifluoroethyl)glutathione in rat and human hepatocytes and in Hep G2 cells.
      E Tanaka and M W Anders
      Drug Metabolism and Disposition January 1995, 23 (1) 48-54;

  5. Tokuma, Y

    1. Further metabolism of FK506 (tacrolimus). Identification and biological activities of the metabolites oxidized at multiple sites of FK506.
      K Iwasaki, T Shiraga, H Matsuda, K Nagase, Y Tokuma, T Hata, Y Fujii, S Sakuma, T Fujitsu and A Fujikawa
      Drug Metabolism and Disposition January 1995, 23 (1) 28-34;

  6. Trimble, L A

    1. In vitro and in vivo biotransformations of the naphthalenic lignan lactone 5-lipoxygenase inhibitor, L-702,539.
      N Chauret, C Li, Y Ducharme, L A Trimble, J A Yergey, C Ramachandran and D A Nicoll-Griffith
      Drug Metabolism and Disposition January 1995, 23 (1) 65-71;

  7. Tsuruda, L S

    1. Metabolism of [14C]naphthalene in the B6C3F1 murine isolated perfused liver.
      L S Tsuruda, M W Lamé and A D Jones
      Drug Metabolism and Disposition January 1995, 23 (1) 129-136;

V

  1. Van Leengoed, L A

    1. Infection (Actinobacillus pleuropneumoniae)-mediated suppression of oxidative hepatic drug metabolism and cytochrome P4503A mRNA levels in pigs.
      M Monshouwer, R F Witkamp, S M Nijmeijer, L A Van Leengoed, J H Verheijden and A S Van Miert
      Drug Metabolism and Disposition January 1995, 23 (1) 44-47;

  2. Van Miert, A S

    1. Infection (Actinobacillus pleuropneumoniae)-mediated suppression of oxidative hepatic drug metabolism and cytochrome P4503A mRNA levels in pigs.
      M Monshouwer, R F Witkamp, S M Nijmeijer, L A Van Leengoed, J H Verheijden and A S Van Miert
      Drug Metabolism and Disposition January 1995, 23 (1) 44-47;

  3. Verheijden, J H

    1. Infection (Actinobacillus pleuropneumoniae)-mediated suppression of oxidative hepatic drug metabolism and cytochrome P4503A mRNA levels in pigs.
      M Monshouwer, R F Witkamp, S M Nijmeijer, L A Van Leengoed, J H Verheijden and A S Van Miert
      Drug Metabolism and Disposition January 1995, 23 (1) 44-47;

  4. Villa, P

    1. Fate of 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (ET18-OME) in malignant cells, normal cells, and isolated and perfused rat liver.
      A Magistrelli, P Villa, E Benfenati, E J Modest, M Salmona and M T Tacconi
      Drug Metabolism and Disposition January 1995, 23 (1) 113-118;

  5. Völkel, H

    1. Nicotine and cotinine accumulation in pigmented and unpigmented rat hair.
      B Gerstenberg, G Schepers, P Voncken and H Völkel
      Drug Metabolism and Disposition January 1995, 23 (1) 143-148;

  6. Voncken, P

    1. Nicotine and cotinine accumulation in pigmented and unpigmented rat hair.
      B Gerstenberg, G Schepers, P Voncken and H Völkel
      Drug Metabolism and Disposition January 1995, 23 (1) 143-148;

W

  1. Waidelich, D

    1. Biotransformation of CI-937 in primary cultures of rat hepatocytes. Formation of glutathione conjugates.
      U Renner, J Blanz, S Freund, D Waidelich, G Ehninger and K P Zeller
      Drug Metabolism and Disposition January 1995, 23 (1) 94-101;

  2. Wang, R W

    1. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes.
      D J Newton, R W Wang and A Y Lu
      Drug Metabolism and Disposition January 1995, 23 (1) 154-158;

  3. Wang, Y

    1. Isoflurane-chlorodifluoroethene interaction in human liver microsomes. Role of cytochrome P4502B6 in potentiation of haloethene metabolism.
      M T Baker, M J Olson, Y Wang, W C Ronnenberg, J T Johnson and A N Brady
      Drug Metabolism and Disposition January 1995, 23 (1) 60-64;

  4. Witkamp, R F

    1. Infection (Actinobacillus pleuropneumoniae)-mediated suppression of oxidative hepatic drug metabolism and cytochrome P4503A mRNA levels in pigs.
      M Monshouwer, R F Witkamp, S M Nijmeijer, L A Van Leengoed, J H Verheijden and A S Van Miert
      Drug Metabolism and Disposition January 1995, 23 (1) 44-47;

Y

  1. Yergey, J A

    1. In vitro and in vivo biotransformations of the naphthalenic lignan lactone 5-lipoxygenase inhibitor, L-702,539.
      N Chauret, C Li, Y Ducharme, L A Trimble, J A Yergey, C Ramachandran and D A Nicoll-Griffith
      Drug Metabolism and Disposition January 1995, 23 (1) 65-71;

  2. Yukawa, T

    1. Ocular absorption, distribution, and systemic absorption of a novel antiglaucoma medication, prostaglandin derivative, in male white rabbits.
      K Higaki, K Kamata, M Takeuchi, K Inazawa, T Chikai, T Hamaguchi, T Yukawa, K Kadono, S Kawahara and M Nakano
      Drug Metabolism and Disposition January 1995, 23 (1) 35-43;

Z

  1. Zeller, K P

    1. Biotransformation of CI-937 in primary cultures of rat hepatocytes. Formation of glutathione conjugates.
      U Renner, J Blanz, S Freund, D Waidelich, G Ehninger and K P Zeller
      Drug Metabolism and Disposition January 1995, 23 (1) 94-101;
Back to top

In this issue

Advertisement